Liquid biopsies represent an innovative approach in oncology, allowing for the analysis of circulating tumor DNA (ctDNA) in a minimally invasive manner. While traditional tissue biopsies and imaging face significant limitations in accurately depicting tumor heterogeneity and monitoring disease progression, droplet digital PCR (ddPCR) technology enhances sensitivity for detecting low-abundance ctDNA. This technology enables precise quantification and could transform cancer diagnostics and patient monitoring, especially in evaluating treatment responses and identifying resistance mutations.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.